Last week, the U.S. Ninth Circuit Court of Appeals denied the FDA’s latest attempt to hide thousands of pages of key government documents related to the agency’s first-ever approval of genetically engineered (GE) salmon for human consumption. The court’s decision is a big win for public transparency and a firm rejection of the Trump administration’s position that it can unilaterally decide whether to withhold government documents from public and court review.
In 2015, the FDA approved a GMO salmon made from the DNA of three different animals: Atlantic salmon, deep water ocean eelpout, and Pacific Chinook salmon. The GE version is intended to grow faster than conventional farmed salmon, reportedly getting to commercial size in half the time.
Even though this is the first time any government in the world has approved a GE animal for commercial sale and consumption, so far the FDA has taken a lackadaisical approach to evaluating the salmon’s potential for harm to wild salmon and the environment. If the GE salmon were to escape, it could threaten wild salmon populations by outcompeting them for scarce resources and habitat, by mating with endangered salmon species, and by introducing new diseases.
If the GE salmon were to escape, it could threaten wild salmon populations by outcompeting them for scarce resources and habitat, by mating with endangered salmon species, and by introducing new diseases
The world’s preeminent experts on GE fish and risk assessment, as well as biologists at U.S. wildlife agencies charged with protecting fish and wildlife, heavily criticized the FDA for failing to evaluate these impacts. But the FDA ignored their concerns, so in March 2016, Earthjustice filed a lawsuit against the agency.
As part of the lawsuit, the FDA is required to compile a record of documents that illuminate the path the agency followed to reach its decision to approve the GE salmon—much like a student is required to show their work for a math problem in middle school. A complete record is essential in all cases. But it is especially important here because the FDA has so far refused to release most of the documents related to its decision, despite repeated requests for that information from Earthjustice’s diverse set of clients under the Freedom of Information Act.